Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Research symbols : AMRX save search
Amneal Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics
Published: 2023-07-26 (Crawled : 13:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M
|
Health Technology
|
| O: -0.33%
H: 2.95%
C: 0.0%
fda drug
Biosimilars Market Research Report 2023 - Global Forecast to 2028 - Patent Expiries of Blockbuster Biologics and Research into New Indications Presents Opportunities
Published: 2023-07-05 (Crawled : 00:00) - prnewswire.com
NVS | News | $97.295 2.29% 0.0% 3.7M
|
Health Technology
|
| O: -1.17%
H: 0.63%
C: 0.22%
LLY | News | $745.06 1.88% 0.0% 2M
|
Health Technology
|
| O: -0.55%
H: 0.97%
C: 0.02%
AMRX | $5.4 0.56% 0.56% 1.4M
|
Health Technology
|
| O: -2.54%
H: 10.78%
C: 10.04%
AMPH | $40.92 1.87% 1.83% 210K
|
Health Technology
|
| O: -0.52%
H: 1.38%
C: -0.38%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: -0.43%
H: 0.48%
C: -0.86%
patent report research global market
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
Published: 2023-05-16 (Crawled : 14:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M
|
Health Technology
|
| O: -0.99%
H: 4.99%
C: 1.5%
biosimilar
Myelofibrosis Treatment Market to Reach $1.16 Billion, Globally, by 2031 at 4.0% CAGR: Allied Market Research
Published: 2023-02-06 (Crawled : 12:00) - prnewswire.com
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
|
| O: 2.88%
H: 1.17%
C: -2.24%
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
|
| O: 1.64%
H: 0.24%
C: -0.17%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.0%
H: 0.98%
C: 0.11%
AMRX | $5.4 0.56% 0.56% 1.4M
|
Health Technology
|
| O: 0.0%
H: 6.58%
C: 4.53%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.37%
H: 0.4%
C: -0.49%
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
|
| O: 0.0%
H: 1.47%
C: 0.9%
GLTO | $0.681 0.32% 110K
|
Health Technology
|
| O: -1.11%
H: 3.36%
C: 1.12%
treatment research market
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
Published: 2022-11-11 (Crawled : 14:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M
|
Health Technology
|
| O: 0.0%
H: 4.62%
C: 3.36%
ipx203 treatment fda drug disease application parkinson’s
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
Published: 2022-03-24 (Crawled : 12:30) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M
|
Health Technology
|
| O: 0.5%
H: 0.25%
C: 0.25%
ipx-203 trial results phase 3
Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
response
Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab
Published: 2021-06-17 (Crawled : 12:15) - biospace.com/
AMRX | $5.4 0.56% 0.56% 1.4M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: -4.14%
fda license application
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.